Coya Therapeutics, Inc. (COYA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $15.00 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Thomas Shrader has given his Buy rating due to a combination of factors that reflect positively on Coya Therapeutics, Inc.’s prospects. The recent resubmission of the Investigational New Drug (IND) application is a significant milestone, potentially allowing the commencement of a Phase 2/3 trial within 30 days. This development suggests alignment between Coya and the FDA regarding the necessary preclinical data, reducing regulatory risk.
Furthermore, the company’s COYA-302 program, which involves the co-administration of two immune modulators, has shown promising results in early trials for ALS and FTD, indicating a reasonable safety profile and potential efficacy. The interest in the upcoming trials is bolstered by the previous stabilization observed in ALS patients and cognitive stability in FTD patients. Additionally, the potential of the COYA-303 program, which combines low-dose IL2 with a GLP-1 receptor agonist, adds another layer of interest, particularly in its application for Alzheimer’s Disease. These factors, combined with a straightforward manufacturing process due to the use of biosimilars, contribute to Shrader’s positive outlook on the stock.
In another report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $14.00 price target.